

Datasheet for ABIN7200657

Recombinant anti-VEGF (Ranibizumab Biosimilar) antibody[Go to Product page](#)

Overview

Quantity:	2 mg
Target:	VEGF (Ranibizumab Biosimilar)
Reactivity:	Human
Host:	Mouse
Antibody Type:	Recombinant Antibody
Clonality:	Monoclonal
Conjugate:	This VEGF (Ranibizumab Biosimilar) antibody is un-conjugated
Application:	Flow Cytometry (FACS), In vivo Studies (in vivo)

Product Details

Purpose:	Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)
Immunogen:	The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.
Fragment:	Fab fragment
Specificity:	The Fab protein ranibizumab specifically binds to the human VEGF-A.
Characteristics:	Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.
Purification:	Protein A affinity column
Purity:	> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterility:	0.2 µm filtered

Product Details

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method.

Target Details

Target:	VEGF (Ranibizumab Biosimilar)
Abstract:	VEGF (Ranibizumab Biosimilar) Products
Target Type:	Biosimilar
Background:	<p>The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.</p> <p>Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.</p>

Application Details

Application Notes:	Functional assay, neutralization.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Concentration:	1 mg/mL
Buffer:	PBS, pH 7.4, no stabilizers or preservatives.
Preservative:	Without preservative
Handling Advice:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Storage:	-20 °C
Storage Comment:	12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Handling

Expiry Date: 12 months